MedTrace Logo

Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream

NCT02918617 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2018-11-16

Study results available
· View outcomes & findings →

Summary

This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride dentifrice containing 1,500 ppm fluoride as sodium monofluorophosphate (MFP).

Conditions

  • Dentin Sensitivity

Interventions

DRUG

Control toothpaste containing Novamin® technology

DRUG

Control toothpaste containing 1500 ppm fluoride as MFP

DRUG

Test toothpaste with nano-HAP (high concentration)

DRUG

Test toothpaste with nano-HAP (low concentration)

DRUG

Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3

DRUG

Control toothpaste without nano-HAP

DRUG

Test toothpaste with nano-HAP (medium concentration)

DRUG

Test cream with nano-HAP (higher concentration)

DRUG

Control cream without nano-HAP

Sponsors & Collaborators

  • Sangi Co., Ltd.

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Bennett T Amaechi, BDS, MS, PhD · University of Texas Health Science Center San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918617 on ClinicalTrials.gov